TR200102766T2 - Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar - Google Patents

Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar

Info

Publication number
TR200102766T2
TR200102766T2 TR2001/02766T TR200102766T TR200102766T2 TR 200102766 T2 TR200102766 T2 TR 200102766T2 TR 2001/02766 T TR2001/02766 T TR 2001/02766T TR 200102766 T TR200102766 T TR 200102766T TR 200102766 T2 TR200102766 T2 TR 200102766T2
Authority
TR
Turkey
Prior art keywords
tryptase inhibitors
ketones used
heterocyclic ketones
peptidyl
prevention
Prior art date
Application number
TR2001/02766T
Other languages
English (en)
Inventor
J. Costanzo Michael
E. Maryanoff Bruce
C. Yabut Stephen
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of TR200102766T2 publication Critical patent/TR200102766T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bulus iltihapli hücre serin proteaz inhibitörleri olan bir dizi peptidil heterosiklik ketinlar ve bilesimleri ve çesitli bagisiklik nedenli iltihapli rahatsizliklarin tedavisi ve önlenmesi için yöntemlerle ilgilidir. Daha ayrintili olarak, bu terkipler triptazin güçlü ve selektif inhibitörleri olmalari nedeniyle astim ve alerjik rinit gibi solunum yolu baglantili iltihapli hastaliklarin tedavisi ve önlenmesinde etkilidir.
TR2001/02766T 1999-01-27 2000-01-13 Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar TR200102766T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11760299P 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
TR200102766T2 true TR200102766T2 (tr) 2001-12-21

Family

ID=22373811

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02766T TR200102766T2 (tr) 1999-01-27 2000-01-13 Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar

Country Status (24)

Country Link
US (2) US6469036B1 (tr)
EP (1) EP1147097A1 (tr)
JP (1) JP2002535394A (tr)
KR (1) KR20010110422A (tr)
CN (1) CN1353701A (tr)
AR (1) AR022427A1 (tr)
AU (1) AU3208500A (tr)
BG (1) BG105762A (tr)
BR (1) BR0007778A (tr)
CA (1) CA2361479A1 (tr)
CZ (1) CZ20012722A3 (tr)
EA (1) EA200100815A1 (tr)
EE (1) EE200100391A (tr)
HK (1) HK1038561A1 (tr)
HR (1) HRP20010601A2 (tr)
HU (1) HUP0201295A3 (tr)
IL (1) IL144577A0 (tr)
NO (1) NO20013666L (tr)
SK (1) SK10742001A3 (tr)
TR (1) TR200102766T2 (tr)
TW (1) TWI229669B (tr)
WO (1) WO2000044733A1 (tr)
YU (1) YU61401A (tr)
ZA (1) ZA200106995B (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
DK1268418T3 (da) * 2000-03-27 2006-09-25 Applied Research Systems Farmaceutisk aktive pyrrolidinderivater som Bax-inhibitorer
ES2261404T3 (es) * 2000-03-27 2006-11-16 Applied Research Systems Ars Holding N.V. Derivados de pirrolidina utiles como inhibidores de bax.
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6797461B2 (en) * 2000-10-27 2004-09-28 Promega Corporation Tryptase substrates and assay for tryptase activity using same
WO2002055073A1 (en) * 2001-01-05 2002-07-18 Kyowa Kakko Kogyo Co., Ltd. Preventives for arthritis
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
GB0103765D0 (en) * 2001-02-15 2001-04-04 Affitech As Assay
AU2002352382A1 (en) * 2001-12-13 2003-06-23 Kowa Company Ltd Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity
AU2003237224A1 (en) * 2002-05-29 2003-12-19 Merck And Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
DE10249304B4 (de) * 2002-10-22 2006-09-28 Cytec Surface Specialties Germany Gmbh & Co. Kg Wäßrige Beschichtungsmittel
US7205384B2 (en) 2003-08-05 2007-04-17 Ortho-Mcneil Pharmaceutical Inc. Process for preparing peptidyl heterocyclic ketone derivatives
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
DE602005002251D1 (de) * 2004-02-10 2007-10-11 Janssen Pharmaceutica Nv Pyridazinonharnstoffe als antagonisten von a4-integrinen
JP2008510726A (ja) * 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
RU2419625C2 (ru) * 2006-05-23 2011-05-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
US7951823B2 (en) * 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2117541A1 (en) * 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
KR101131238B1 (ko) 2007-02-09 2012-03-30 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
KR20090108131A (ko) 2007-02-09 2009-10-14 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
ES2351323B1 (es) * 2009-06-26 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
ES2676412T3 (es) 2011-06-02 2018-07-19 Socpra Sciences Santé Et Humaines S.E.C. Inhibidores de matriptasa y usos de los mismos contra infecciones por ortomixovirus
CN103145598B (zh) * 2011-12-07 2014-10-15 北京京卫顺康医药科技发展有限公司 一种奥沙西罗晶体及含有该晶体的组合物
CN105849102B (zh) * 2013-10-29 2020-10-16 生物马林药物股份有限公司 作为葡萄糖基神经酰胺合酶抑制剂的n-(1-羟基-3(吡咯烷基)丙烷-2-基)吡咯烷-3-甲酰胺衍生物
ES2819218T3 (es) 2014-10-06 2021-04-15 Cortexyme Inc Inhibidores de lisina gingipaína
WO2016144654A1 (en) * 2015-03-09 2016-09-15 Washington University Inhibitors of growth factor activation enzymes
WO2017083433A1 (en) * 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
KR102780603B1 (ko) 2016-09-16 2025-03-12 라이트하우스 파마슈티컬스, 인코포레이티드 리신 진지파인의 케톤 억제제
AU2018265397A1 (en) * 2017-05-10 2019-11-28 Cortexyme, Inc. Aminopyridine compounds and methods for the preparation and use thereof
EP4159211A4 (en) 2021-07-15 2024-10-30 National Center for Global Health and Medicine ASSOCIATED WITH PHYSIOLOGICAL ACTIVITY SUCH AS ANTIVIRAL ACTIVITY

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525623A (en) 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
JPH0820597A (ja) 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
JPH11508535A (ja) 1994-12-22 1999-07-27 バイオケム ファーマ インコーポレイテッド 低分子量２環式トロンビン阻害剤
JPH10513151A (ja) 1994-12-22 1998-12-15 バイオケム ファーマ インコーポレイテッド トロンビン阻害剤としての複素環式ケトアルギニンペプチド
AU713530B2 (en) 1995-03-24 1999-12-02 Molecumetics, Ltd. Beta-sheet mimetics and use thereof as protease inhibitors
WO1996030396A1 (en) 1995-03-24 1996-10-03 Molecumetics Ltd. β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
GB9510264D0 (en) 1995-05-22 1995-07-19 Iaf Biochem Int Low molecular weight bicyclic-urea type thrombin inhibitors
US5523308A (en) 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6069130A (en) * 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5827860A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
ES2262184T3 (es) 1996-08-05 2006-11-16 Myriad Genetics, Inc. Utilizacion de mimeticos de hojas beta como inhibidores de proteasa y de kinasa o como inhibidores de factores de transcripcion.
WO1998009987A1 (en) 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
WO1999026925A1 (en) 1997-11-26 1999-06-03 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitors comprising heterocyclic amide compounds
ES2273445T3 (es) 1997-12-16 2007-05-01 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Composiciones y procedimientos para regular la fagocitosis y la expresion de icam-1.

Also Published As

Publication number Publication date
AR022427A1 (es) 2002-09-04
TWI229669B (en) 2005-03-21
EA200100815A1 (ru) 2002-08-29
SK10742001A3 (sk) 2002-08-06
EE200100391A (et) 2002-10-15
AU3208500A (en) 2000-08-18
KR20010110422A (ko) 2001-12-13
NO20013666L (no) 2001-09-26
EP1147097A1 (en) 2001-10-24
HRP20010601A2 (en) 2002-08-31
IL144577A0 (en) 2002-05-23
BR0007778A (pt) 2002-06-04
BG105762A (en) 2002-03-29
NO20013666D0 (no) 2001-07-26
US7132418B2 (en) 2006-11-07
JP2002535394A (ja) 2002-10-22
CA2361479A1 (en) 2000-08-03
ZA200106995B (en) 2002-11-25
HUP0201295A3 (en) 2002-10-28
WO2000044733A1 (en) 2000-08-03
CZ20012722A3 (cs) 2002-08-14
YU61401A (sh) 2005-07-19
HUP0201295A2 (en) 2002-09-28
CN1353701A (zh) 2002-06-12
HK1038561A1 (zh) 2002-03-22
US20030008829A1 (en) 2003-01-09
US6469036B1 (en) 2002-10-22

Similar Documents

Publication Publication Date Title
YU61401A (sh) Peptidil heterociklični ketoni korisni kao inhibitori triptaze
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
ATE457313T1 (de) Bicyclische heterocyclische p-38-kinase- inhibitoren
TR200103390T2 (tr) Proteaz inhibitörleri olan yeni bileşikler ve terkipler.
ATE189211T1 (de) Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten
SE0201980D0 (sv) Novel compounds
NO20070201L (no) Seksleddede heterocykler anvendelige som serinproteaseinhibitorer
WO2005099709A3 (en) Bicyclic heterocycles useful as serine protease inhibitors
ATE439837T1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
UA74372C2 (uk) Інгібітори серинових протеаз, фармацевтична композиція на їх основі
EP1585482A4 (en) NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20020217D0 (no) Nitrogenholdige heterobicykler som faktor Xa-inhibitorer
NO983688L (no) Serin-protease-inhibitorer
MY138303A (en) Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
DE60105418D1 (de) Serinprotease-inhibitoren
SE0201977D0 (sv) Novel compounds
ATE303989T1 (de) Inhibitoren von serin proteasen
DE60129132D1 (de) Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
EP1611120A4 (en) NEW METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES
DE602004007672D1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
ECSP055844A (es) Nuevos compuestos triciclicos
SE0203712D0 (sv) Novel compounds
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
EA200501463A1 (ru) Новые соединения фосфоновой кислоты в качестве ингибиторов серинпротеаз